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ABSTRACT
Discrimination of pancreatic ductal adenocarcinoma (PDAC) from chronic 
pancreatitis (CP) or peritumoral inflammation is challenging, both at preoperative 
imaging and during surgery, but it is crucial for proper therapy selection. Tumor-specific 
molecular imaging aims to enhance this discrimination and to help select and stratify 
patients for resection. We evaluated various biomarkers for the specific identification 
of PDAC and associated lymph node metastases. Using immunohistochemistry (IHC), 
expression levels and patterns were investigated of integrin αvβ6, carcinoembryonic 
antigen-related cell adhesion molecule 5 (CEACAM5), Cathepsin E (Cath E), epidermal 
growth factor receptor (EGFR), hepatocyte growth factor receptor (c-MET), thymocyte 
differentiation antigen 1 (Thy1), and urokinase-type plasminogen activator receptor 
(uPAR). In a first cohort, multiple types of pancreatic tissue were evaluated (n=62); 
normal pancreatic tissue (n=8), CP (n=7), PDAC (n=9), tumor associated lymph 
nodes (n=32), and PDAC after neoadjuvant radiochemotherapy (n=6). In a second 
cohort, tissues were investigated (n=55) with IHC and immunofluorescence (IF) for 
concordance of biomarker expression in all tissue types, obtained from an individual 
patient. Integrin αvβ6 and CEACAM5 showed significantly higher expression levels 
in PDAC versus normal pancreatic tissue (P=0.001 and P<0.001, respectively) and 
CP (P=0.003 and P<0.001, respectively). Avβ6 and CEACAM5 expression identified 
tumor-positive lymph nodes correctly in 84% and 68%, respectively, and in 100% 
of tumor-negative nodes for both biomarkers. In conclusion, αvβ6 and CEACAM5 are 
excellent biomarkers to differentiate PDAC from surrounding tissue and to identify 
lymph node metastases. Individually or combined, these biomarkers are promising 
targets for tumor-specific molecular imaging of PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is 
predicted to become the second cause of cancer-related 
death in 2030 [1]. Patients with PDAC have a dismal 
prognosis, with a five-year survival rate of less than 5% 
[2]. At this point, complete surgical resection is the only 
potential curative treatment. However, at the time of 
primary diagnosis, 75% to 85% of patients has advanced 
unresectable disease due to locoregional spread and 
metastasis [3, 4]. Therefore, accurate identification of 
potential candidates for resection is crucial to prevent 
unnecessary surgical risks and delay in systemic therapy 
[5]. Another challenge during surgery, is that despite 
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careful selection of resectable patients using CT, MRI 
and/or PET imaging, incomplete (R1) resection occurs in 
up to 70% of cases [6]. Failure to identify tumor-positive 
margins during surgery is not surprising, and is due to 
the tumor’s characteristic to quickly spread beyond the 
pancreas via perineural and perivascular pathways [7] 
and the inability of the surgeon to differentiate between 
tumor and (peritumoral) inflammatory pancreatic tissue 
[8, 9]. This is also challenging in pre-operative imaging 
with conventional technique since both PDAC and chronic 
pancreatitis (CP) may present similar due to abundant 
stroma.
To improve surgical outcomes, novel neoadjuvant 
treatment protocols, such as FOLFIRINOX, are 
being successfully implied in the treatment of PDAC. 
Unfortunately, a drawback of these neoadjuvant 
therapies is that current imaging modalities are unable to 
differentiate between vital tumor and radiochemotherapy-
induced tumor necrosis and fibrosis [10–12]. In addition, 
neoadjuvant treatment effects worsen the ability of 
the surgeon to differentiate (vital) tumor from fibrotic 
pancreatic tissue and often times, serial frozen section 
analysis is required to assess whether to continue a 
resection.
Tumor imaging using molecularly targeted probes 
has the potential to play an important role in improving 
patient management and treatment in these situations. 
This technique can be used for tumor detection, 
characterization, staging, and response assessment to 
neoadjuvant treatment. Moreover, it can facilitate image-
guided therapy, and provide surgical guidance during 
tumor resection [13]. Recently, a first-in-human study was 
conducted using intra-operative tumor-specific imaging. A 
targeting ligand combined with a fluorophore was used for 
the detection of tumor-specific biomarkers for diagnostic 
imaging and surgical decision-making in ovarium cancer 
[14].
For tumor-specific imaging, a biomarker is required 
to function as a target. In PDAC, a large number of 
biomarkers are known to be overexpressed. However, a 
limited number of these markers are eligible candidates 
for targeted imaging. Potential biomarkers for tumor-
specific targeting must possess certain characteristics, 
such as homogeneous expression, upregulation of more 
than ten times compared to normal and surrounding 
tissue, and localization on the cellular membrane 
[15–17]. A preliminary study from our own research 
group identified several potential targets which are 
overexpressed in pancreatic tumor compared to normal 
pancreatic tissues; integrin αvβ6, carcinoembryonic 
antigen (CEA), epidermal growth factor receptor (EGFR), 
and urokinase plasminogen activator receptor (uPAR) 
[18]. These biomarkers have also shown their potential 
for tumor-targeted imaging in pre-clinical studies 
[15, 19–31]. However, a potential target for clinically 
relevant differentiation between PDAC and peritumoral 
inflammation or CP has yet to be identified. Next to the 
ability to discriminate PDAC from CP, the target also 
needs to be able to identify lymph node metastases and 
differentiate between vital tumor cells versus necrosis and 
fibrosis in patients that have received neoadjuvant therapy.
The primary aim of this study was to evaluate 
the ability of integrin αvβ6, carcinoembryonic antigen-
related cell adhesion molecule 5 (CEACAM5), Cathepsin 
E (Cath E), EGFR, hepatocyte growth factor receptor 
(c-MET), thymocyte differentiation antigen 1 (Thy1), 
and uPAR as targets to differentiate between PDAC, CP 
and normal pancreatic tissue for tumor-specific imaging 
and for the potential to develop clinically translatable 
imaging agents targeting these markers. The biomarkers 
were selected based on a literature search and our 
previous study using tissue microarrays (TMA) of 137 
patients [18, 19, 32, 33].
RESULTS
In the first cohort, a total of 62 tissues (n=8 PDAC, 
n=7 CP, n=9 normal pancreatic tissue, n=32 lymph nodes, 
n=6 PDAC after neoadjuvant radiochemotherapy) were 
stained for all biomarkers to assess expression patterns. In 
the second cohort, a total of 55 tissue slides were stained 
with the two most suitable biomarkers (n=12 PDAC, n=12 
CP, n=12 normal pancreatic tissue, n=19 lymph nodes). 
Patient and tumor characteristics are summarized in 
Supplementary Table 1.
Avβ6, CEACAM5, CathE and uPAR are 
significantly higher expressed in PDAC 
versus CP
All biomarkers were overexpressed in PDAC, 
except for c-MET (Figure 1S-1U) and Thy 1 (Figure 
1J-1L), which showed equal or even higher staining 
in normal pancreatic tissue or CP compared to PDAC. 
Although there was abundant Thy1 stromal staining 
in PDAC, it was also present in stroma of adjacent 
normal and inflamed pancreatic tissue. Therefore, both 
targets were excluded from further analysis. All other 
targets showed significant higher expression in PDAC 
compared to normal pancreatic tissue; αvβ6 (Figure 1A-
1C) (p <0.001), CEACAM5 (Figure 1D-1F) (p <0.001), 
EGFR (Figure 1G-1I) (p <0.05), Cath E (Figure 1P-
1R) (p <0.001), and uPAR (Figure 1M-1O) (p <0.001). 
Avβ6 was homogeneously expressed, uPAR, and Cath 
E were slightly heterogeneously expressed, and all 
other biomarkers showed a markedly heterogeneous 
expression pattern in PDAC tissue (Supplementary 
Figure 1). Furthermore, only CEACAM5 expression in 
PDAC was slightly more intense in the invasive border 
compared to the tumor core. The following biomarkers 
were significantly overexpressed in PDAC versus CP; 
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αvβ6 (Figure 1B-1C) (p<0.001), CEACAM5 (Figure 1E-
1F) (p <0.001), Cath E (Figure 1Q-1R) (p <0.001), and 
uPAR (Figure 1N-1O) (p <0.001). All targets, except 
for CEACAM5, showed expression in the duodenum 
especially at the luminal side (not shown). This was also 
the case in colonic tissue where there was luminal staining 
for most targets except for uPAR (not shown).
Interestingly, immunohistochemical staining for 
CEACAM5 (Supplementary Figure 2) and uPAR showed 
complete absence of staining in normal pancreatic 
parenchyma. Avβ6 showed moderate staining in normal 
ductal structures, but there was a significantly higher 
expression in malignant ducti. The substantially higher 
ratio of ductal structures in malignant pancreatic tissue 
compared to normal pancreatic parenchyma adds to the 
significant increase of marker expression per high power 
field. (Supplementary Figure 3).
Avβ6 specifically differentiates tumor-positive 
and tumor-negative lymph nodes
Next, we investigated biomarker expression in 
tumor-positive and –negative lymph node. A total of 17 
tumor-positive and 15 tumor-negative nodes were stained. 
The described biomarkers identified the investigated 
tumor-positive and -negative lymph nodes correctly with, 
respectively, a sensitivity and specificity of; αvβ6 (84%; 
100%), CEACAM5 (68%; 100%), EGFR (93%; 67%), 
Figure 1: Expression patterns of investigated markers. Representative images of immunohistochemically staining patterns in 
PDAC of all molecular markers; αvβ6 (A-C), CEACAM5 (D-F), EGFR (G-I), Thy1 (J-L), uPAR (M-O), CathE (P-R), cMET (S-U) 
showing respectively from left to right normal pancreatic tissue, CP, PDAC and graphical representation of mean percentage staining on all 
the tissue slides (*: p<0.05, **: p<0.01, ***: p<0.001).
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Cath E (54%; 83%), and uPAR (69%; 67%). Figure 2 
shows biomarker expression in tumor-positive lymph 
nodes for all investigated biomarkers.
An interim analysis to assess the suitability of the 
biomarker panel as targets for tumor-specific molecular 
imaging of PDAC was performed, shown in Table 1. 
Biomarkers αvβ6 and CEACAM5 met most of the criteria 
of an optimal tumor-specific biomarker and were selected 
for further evaluation.
Biomarker patterns change after neoadjuvant 
radiochemotherapy
Molecular targeted imaging could be useful 
tool for neoadjuvant therapy response monitoring. 
The consequence of neoadjuvant therapy on αvβ6 and 
CEACAM5 expression was assessed by staining tissues 
from patients who received radiochemotherapy. In all 
investigated neoadjuvantly treated tumors, there was a 
markedly higher αvβ6 expression seen in the remaining 
vital tumor cells compared to the surrounding fibrosis 
and necrosis, as shown in Figure 3A and 3B. This 
level of expression was comparable to the expression 
in PDAC without neoadjuvant therapy, as previously 
shown. CEACAM5 expression in vital tumor cells after 
neoadjuvant therapy was reduced, as shown in Figure 
3C, compared to PDAC not treated neoadjuvantly. As 
a result, no difference in expression of CEACAM5 
between vital tumor cells and surrounding fibrosis and 
necrosis was seen (Figure 3C and 3D). In the samples 
of two out of six patients there was no expression of 
CEACAM5 in the remaining vital PDAC cells. Due 
to small sample size, we were not able to determine 
significance of results.
Avβ6 and CEACAM5 expression is markedly 
different between normal pancreatic 
parenchyma, peritumoral inflammation, and 
PDAC of individual patients
In a second cohort, normal pancreatic parenchyma, 
peritumoral inflammation and PDAC of individual patients 
(n=12) were included in order to mimic the actual clinical 
situation. In 11 out of 12 patients, αvβ6 staining in PDAC 
was clearly higher compared to inflammation and to normal 
pancreatic parenchyma (4 and 2 times higher, respectively). 
CEACAM5 expression was only present in PDAC, and 
therefore, the staining pattern was markedly different 
between normal pancreatic parenchyma, peritumoral 
inflammation and PDAC in all patients except for two who 
did not express CEACAM5 in any of their tissue samples 
(Supplementary Figure 4). In concordance with the first 
patient cohort, CEACAM5 staining of PDAC was weaker 
and more heterogeneous compared to αvβ6. In Figure 4, 
expression of CEACAM5 (Figure 4B) and αvβ6 (Figure 4C) 
in PDAC, peritumoral inflammation, and normal pancreatic 
parenchym of one individual patient are presented next to 
Figure 2: Biomarker expression in tumor-positive lymph nodes. Biomarker expression in tumor-positive lymph nodes for the 
different biomarkers αvβ6 (A), CEACAM5 (B), EGFR (C), uPAR (D), CathE (E) (Objective 1x, insert 20x).
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the corresponding H&E stain (A), showing the difference in 
expression even in such close proximity.
Multiplexing for optimal discrimination between 
malignant and benign tissue
Double staining of CEACAM5 and αvβ6 
using immunofluorescence showed that multiplexing 
by targeting both biomarkers leads to an improved 
discrimination between malignant and benign pancreatic 
tissue and identification of all PDAC tissue. Examples 
of using multiplexing to achieve improved detection are 
shown in Figure 5, and Supplementary Figure 5. This 
improved detection is obtained by the different expression 
patterns of both targets, as also shown in Figure 1, which 
are complementary to each other. Targeting αvβ6 will 
identify all PDAC as shown above, and CEACAM5 
reduce the false positive staining by αvβ6 in normal 
pancreatic parenchyma and CP.
Table 1: Suitability of biomarkers
Target Localization
Upregulation 
in PDAC 
compared to 
normal
Upregulation 
in PDAC 
compared 
to CP
Sensitivity 
of target 
for lymph 
node 
metastases
Diffuse 
upregulation 
throughout 
the tumor
Main 
advantage
Main 
disadvantage
αvβ6
Cell 
membrane p<0.001 p<0.001 84% ++
Diffuse, strong 
expression.
Expression on 
normal ductal 
structures.
CEACAM5
Cell 
membrane p<0.001 p<0.001 68% +
No expression 
in normal 
pancreatic tissue 
and CP.
Heterogeneous 
expression 
and loss of 
expression after 
neoadjuvant 
treatment.
EGFR
Cell 
membrane p=0.031 p=1.000 93% ++
EGFR-mediated 
cellular 
internalization 
of targeted 
particles.
Relatively high 
expression on 
normal duodenal 
tissue, thereby 
changing 
surgical field.
uPAR Cell membrane p<0.001 p<0.001 69% ++
Expression 
both on tumor 
and tumor 
surrounding 
stromal cells.
High uPAR 
expression in 
negative lymph 
nodes.
CathE Intracellular p<0.001 p<0.001 54% +
Ideal for 
imaging 
purposes due 
to possible use 
of activatable 
probes, and 
therefore 
increasing 
signal-to-
background 
ratio.
Intracellular 
location of 
target requires a 
probe capable of 
internalization.
Overview of the characteristics of the analyzed biomarkers for determination of the suitability of the biomarker as tumor-
target for molecular-imaging during pancreatic cancer surgery; Integrin Avβ6, carcinoembryonic antigen (CEACAM5), 
epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (or c-MET), urokinase-type plasminogen 
activator receptor (uPAR), and Cathepsin E (Cath E). No upregulation (-). Heterogeneous upregulation in tumor (+). Diffuse 
expression of target (++).
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DISCUSSION
Imaging using tumor-specific molecular probes has 
the potential to solve some of the challenges regarding 
PDAC diagnosis, treatment response monitoring and 
surgery. For tumor-specific molecular imaging to be 
successful, it is essential to have suitable biomarkers 
that can be targeted by molecular probes and are able to 
distinguish primary PDAC and metastases from normal 
pancreatic tissue, CP or acute (peritumoral) inflammation. 
With the current imaging modalities, the differentiation 
between PDAC and CP remains a challenge as still 7-13% 
Figure 3: Biomarker expression after neoadjuvant therapy. In all neoadjuvant treated tissue a markedly higher αvβ6 expression 
was identified in vital tumor tissue (A) compared to surrounding fibrosis or necrosis (B) after neoadjuvant therapy. CEACAM5 biomarker 
expression showed increased heterogeneity after neoadjuvant therapy in the tumor (C), therefore clear distinction between vital tumor and 
fibrosis and necrosis is not possible (C and D) (Objective 10x).”
Figure 4: Biomarker expression in different tissue types within one patient. Expression of CEACAM5 (B) and αvβ6 (C) of 
one individual patient with the corresponding H&E slide (A) in PDAC (above red line), peritumoral inflammation (between red lines), 
and normal pancreatic parenchyma (below red lines), showing the difference in expression even in such a close proximity (Objective 2x).”
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of pancreatectomies are performed for benign pathology 
[34]. Molecular imaging can potentially also improve 
the outcome of PDAC patients by providing the ability 
to identify small tumor nodules in an early stage and 
therefore increasing the chance of cure and improving 
survival rates [35, 36]. Another major problem for PDAC 
surgery is the high recurrence rate within 6-12 months, 
which suggests that local or distant micrometastases 
were already present at the time of surgery [37, 38]. This 
underscores that conventional imaging modalities (i.e., 
MRI, CT and PET) lack the sensitivity to detect small 
amounts of tumor leading to highly morbid surgical 
procedures for patients without the desired oncologic 
benefit. A technique that improves the stratification of 
patients to ensure receivement of the proper therapy could 
serve as a helpful tool for personalized treatment in PDAC. 
Examples of tumor-specific imaging modalities include: 
ultrasound, CT, PET, and fluorescent optical imaging. 
Fluorescent optical imaging has shown the ability to 
detect lesions <2mm as described by Warram, et al. [39]. 
Of course, this modality can only be used during surgery 
but will lead to better stratification intraoperatively.
For PDAC, the greatest improvements in patient 
outcome would likely be the result of better selection 
of patients for surgery, preoperative visualization of all 
tumor-positive lymph nodes and distant metastases, or 
the decision to abort surgery in a noncurative procedure. 
This study implies that molecular imaging using tumor-
specific targets, such as αvβ6 and CEACAM5, can help 
to guide this process. The main advantage of the present 
study is the use of tissue sections that represent a cross 
section of the entire pancreas which is preferred above 
tissue microarray (TMA) cores, as we could assess exact 
staining patterns more thoroughly in a larger surface and 
can recognize heterogeneity more reliably. This change in 
technique potentially explains why substantially higher 
expression rates are found in normal ductal pancreatic 
tissue compared to the literature [18, 32, 40]. To assess 
clinical relevance of the technique and represent the 
clinical situation during imaging and surgery, PDAC, 
lymph nodes, CP and peritumoral inflammation as well 
as unremarkable pancreatic parenchyma were included 
from the same unique patients. To our knowledge, this is 
the first report comparing the expression of biomarkers 
not only in different tissue types but also in benign and 
malignant lesions within the same organ from a single 
patient leading to the identification of ideal biomarkers 
for preoperative and intraoperative imaging [27, 28, 30, 
41]. The results of CEACAM5 and αvβ6 in PDAC tissues 
are in line with most previous reports [21, 27, 30, 31]. 
However in contrast, Allum et al. and Jewkes et al. both 
reported CEA staining in CP [28, 42]. For their study, 
they used the monoclonal anti-CEA antibodies, 11-285-14 
and 11-359-6, but it is unknown if their antibodies were 
directed against CEACAM5 or another subtype of CEA.
The fact that CEACAM5 could be a potential 
biomarker for the tumor-specific identification of PDAC 
would lead to other advantages. CEA is known to be 
Figure 5: Value of multiplexing in PDAC. Immunofluorescent staining of αvβ6 and CEACAM5 simultaneously in PDAC. Showing 
the additional value of using two biomarkers to target all tumor tissue compared to one biomarker (Objective 40x).
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present in soluble form in the serum for multiple cancer 
types. Recent studies have reported a positive relation 
between CEA levels in cancer tissue and serum CEA 
levels [43, 44], while other studies did not show this 
relation [45–48]. For now, this phenomena is mainly 
studied in colorectal cancer and the correlation between 
serum CEA and tissue CEA in PDAC is unclear, but is 
subject of investigation in our group.
As shown in this study as well as in literature, no 
individual biomarker is perfect. For most tumor types, 
one unique biomarker is not sufficient for exact tumor-
specific identification, and therefore the potential to 
perform multiplexing is crucial. In this study, we showed 
the advantage of using probes with different fluorescent 
labels for multiplexing purposes, An example of a 
technique which is optimal for multiplexing is Raman 
imaging. Several different nanoparticles can be produced 
by modifying the Raman surface and therefore generating 
unique spectral signatures [49]. Unfortunately, this 
technique is still far from wide clinical use. To target 
multiple biomarkers with fluorescence imaging, diabodies 
are the ligand of choice now. However, if a diabody was 
used with one fluorescent label to target CEACAM5 and 
αvβ6, exact differentiation would not have been possible 
between normal pancreatic tissue, CP and inflammation, 
and PDAC since both targets have their own strengths 
in this differentiation. Targeting both biomarkers with 
different fluorescently-labeled ligands might thus be 
beneficial for imaging purposes.
Since the successful introduction of novel 
neoadjuvant regimens for PDAC, like FOLFIRINOX, 
resectability rates have increased up to 51% [50]. 
However, a major drawback of this success is that after 
neoadjuvant treatment conventional imaging modalities 
are not able to differentiate between vital tumor cells and 
radiochemotherapy-induced tumor necrosis and fibrosis, 
and are therefore no longer able to predict resectability 
[10]. A potential role for targeted imaging, would 
require that parts of the tumor that have remained vital 
tumor after neoadjuvant therapy would have to retained 
their expression levels. Avβ6 was shown to possess that 
capacity. CEACAM5 expression, on the other hand, was 
reduced compared to PDAC tissue without neoadjuvant 
treatment. Two potential explanations for this effect could 
be: (i) there is tumor heterogeneity where the subtype with 
CEACAM5 expression is selectively killed by the (radio)
chemotherapy [51–53], or (ii) the neoadjuvant therapy 
has a selective effect on the cell genome [54]. However, 
before final conclusions can be drawn in neoadjuvant 
treated tissues, these results need to be validated in a larger 
series of patients. Another limitation of our approach 
in this series is that the biomarker expression before 
(radio)chemotherapy is unknown. However, based on 
the available literature and our presented results, we feel 
confident that biomarker expression of these tumors prior 
to therapy is comparable to expression in tumors that are 
not treated with neoadjuvant therapy.
A potential hurdle for the clinical translation of 
tumor-targeted imaging could be the need for agents 
directed against different targets in the various cancer 
types, which is costly and a regulatory burden. For 
example, the role of c-MET as a biomarker in fluorescence 
imaging seems to be cancer type-specific. Burggraaf 
et al. showed the potential of c-MET as biomarker in 
colon cancer [55], whereas in PDAC, its role is less 
clear. In this study, as with others, c-MET shows relevant 
overexpression in normal pancreatic tissue, excluding it as 
target for tumor-specific molecular imaging applications 
[56]. Also biomarkers targeting stromal components and 
microenvironment such as uPAR and Thy1 are suggested 
for molecular imaging of cancer [19, 57]. However, as 
shown, biomarkers targeting the microenvironment of 
PDAC, are less useful when extravasation occurs because 
abundant stroma exists not only in PDAC, but also in 
normal pancreatic tissue and especially in chronic and 
acute pancreatitis. Another main disadvantage of uPAR 
was the expression in negative lymph nodes, potentially 
due to its natural expression on macrophages. This is 
in line with a recently published review paper from 
Petrushnko et al [58]. Since lymph node identification was 
one of our main criteria, uPAR was not included in the 
second cohort for evaluation although it performed similar 
to CEACAM5 on several other characteristics.
In conclusion, both CEACAM5 and αvβ6 are 
promising candidates for tumor-specific molecular imaging 
for PDAC. Especially when used in combination, these 
biomarkers can discriminate between normal pancreatic 
tissue, CP and peritumoral inflammation, and PDAC. 
And in addition, can identify lymph node metastases. 
Also, αvβ6 can help identify vital tumor after neoadjuvant 
radiochemotherapy. Therefore, agents recognizing both 
biomarkers, combined with a different label or two separate 
agents, would have the potential to create a huge impact in 
PDAC diagnostics, therapy and patient outcome.
MATERIALS AND METHODS
Patient and tissue selection
Medical records and tissue specimens were 
retrospectively reviewed from patients who underwent 
pancreatic resection at the Leiden University Medical 
Center (LUMC) and Erasmus Medical Center (EMC) in 
Rotterdam between January 2011 and September 2015. 
Patients were selected with the histological diagnosis 
PDAC (n=8) or CP (n=7). In addition, normal pancreatic 
tissue lying adjacent to a PDAC was obtained from nine 
patients (n=9). Locoregional lymph nodes (n=32; n=17 
tumor-negative, n=15 tumor-positive) were included 
from the PDAC patients to identify biomarker expression 
in lymph node metastasis. For our second cohort, all 
tissues (n=55; normal pancreatic parenchyma, inflamed 
pancreatic tissue, and PDAC tissue) were obtained from 
individual patients (n=12). All tissue samples were 
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reviewed by a specialized pathologist before inclusion 
in the study. Tumor differentiation grades according to 
guidelines established by the World Health Organization 
were included. Colonic (n=3) and duodenal tissues 
(n=3) (from Department of Pathology, LUMC) were 
included as controls to assess biomarker expression in 
the peripancreatic organs. Patterns of expression of tumor 
biomarkers on pancreatic surgical specimens following 
neoadjuvant therapy were assessed in a small cohort (n=6) 
of patients who received radiochemotherapy; three cycles 
of gemcitabine and 15 fractions of 36 Gy radiotherapy 
during two cycles (PREOPANC trial).
Antibodies and reagents
The antibodies used for immunohistochemical 
(IHC) staining are shown in Supplementary Table 2.
Immunohistochemistry on tissue sections
Formalin-fixed, paraffin-embedded (FFPE) tissue 
blocks were collected from the Pathology Department of 
the LUMC and EMC. Tissue sections of 5 μm thickness 
were obtained from two different types of tissue blocks, 
one type with standard measurement of 40 x 26 mm, 
and the other type of 75 x 50 mm. The second type 
was used to determine the expression pattern across the 
entire specimen. All tissue slides used in the study were 
immunohistochemically assessed. For the second cohort of 
slides, additional immunofluorescence was performed. For 
preparation of IHC staining, the slides were deparaffinized 
with xylene and rehydrated in serially diluted ethanol 
solutions (100%-50%), followed by demineralized water 
according to standard protocols. Endogenous peroxidase 
activity was blocked by incubation in 0.3% hydrogen 
peroxidase in phosphate buffered saline (PBS) for 20 
min. Antigen retrieval for CEACAM5, Thy1, and uPAR 
was performed by heat induction at 95°C using PT Link 
(Dako) with low-pH Envision FLEX target retrieval 
solution (pH 6.0, citrate buffer, Dako). For c-MET and 
Cath E, the high-pH Envision FLEX target retrieval 
solution was used (pH 9.0, citrate buffer, Dako). For αvβ6 
and EGFR staining, antigen retrieval was performed with 
0.4% pepsin incubation (Dako) at 37°C for 10 min.
Following antigen retrieval, the tissue sections were 
incubated overnight with the primary antibodies in 100 
μl for standard tissue sections and 500 μl for the large 
tissue sections at room temperature. A pre-determined 
optimal dilution was used for all antibodies; anti-αvβ6 
antibodies 1:800, anti-CEACAM5 antibodies 1:1000, 
anti-EGFR antibodies 1:100, anti-CD90/Thy1 antibodies 
1:800, anti-MET antibodies 1:8000, anti-Cath E antibodies 
1:1000, and anti-uPAR antibodies 1:800. The slides 
were washed with PBS, followed by incubation with 
secondary antibody for 30 minutes at room temperature. 
After additional washing, the staining was visualized 
with 3,3-diaminobenzidine tetrahydrochloride solution 
(DAKO, Glustrup, Denmark) at room temperature for 
5 minutes and counterstained with hematoxylin for 20 
seconds. Finally, the tissue sections were dehydrated and 
mounted in Pertex (Histolab, Rockville, MD, USA).
IHC analysis
All stained sections with standard measurements (40 
x 26 mm) were scanned and viewed at 40x magnification 
using the Philips Ultra-Fast Scanner 1.6 RA (Philips, 
Eindhoven, Netherlands). The large tissue sections 
were viewed under the microscope. Evaluation of the 
immunohistochemical staining was performed blinded 
independently by two observers (W.S.F.J.T. and A.F.S.). 
The following scoring method was used; percentage 
specific staining (normal/PDAC/CP) was scored as 
percentage of total tissue 0=<10%, 1=10-25%, 2=26-50%, 
3=51-75%, 4=>75%. Staining intensity was scored as 
0=none, 1=weak, 2=moderate, 3=strong (Supplementary 
Figure 6). Undesired staining of structures other than 
investigated tissues (i.e., normal/tumor/inflammation/
stroma) was scored as 0=none, 1=moderate, 2=strong. In 
tumor tissue, a comparison was made between staining 
at invasive border compared to core of the tumor. This 
was scored as tumor core vs invasive border: 0=lower, 
1=similar, 2=stronger.
Interim analysis to assess biomarker suitability
Primary analysis of all biomarker characteristics 
included expression pattern, expression in normal 
pancreatic parenchyma, pancreatitis, PDAC and 
expression in tumor-positive and tumor-negative lymph 
nodes. Next an interim analysis of the different biomarkers 
was performed to assess the suitability of these markers 
as targets for tumor-specific molecular imaging of PDAC. 
After this analysis the most suitable biomarkers (αvβ6 
and CEACAM5) were chosen for further assessment to 
specifically identify their potential in clinically relevant 
situations, tailored to tumor-specific molecular imaging.”
Immunofluorescence
Double immunofluorescent staining of αvβ6 and 
CEACAM5 was performed on FFPE tissue sections of 
normal pancreatic tissue, PDAC, and CP. The slides were 
treated similar as described above. Antigen retrieval for 
both targets was performed by heat induction at 95°C 
using PT Link with a low-pH Envision FLEX target 
retrieval solution. Sections were incubated with 5% Fetal 
Bovine Serum in PBS for 10 minutes at room temperature 
prior to incubation with primary antibodies. Both primary 
antibodies against αvβ6and CEACAM5 were applied 
overnight at room temperature. These were detected using 
secondary antibodies mentioned before; anti-IgG1-AF488 
Oncotarget56825www.impactjournals.com/oncotarget
for αvβ6 and anti-IgG2a-AF647 for CEACAM5. After 
washing three times in PBS, nuclei were stained with 
4',6-diamidino-2-phenylindole (DAPI, Prolong Gold, Life 
Technologies) and stored at 4°C. The slides were examined 
using a Leica DM5500B digital fluorescence microscope 
(Leica Microsystems B.V., Son, the Netherlands) equipped 
with a Leica DFC365FX camera using LAS X software 
for image acquisition and processing.
Statistical analysis
The statistical analysis was performed using 
SPSS version 20.0 software for Windows (SPSS, IBM 
Corporation, Somer NY, USA) and GraphPad Prism 
6 (GraphPad, Software, Inc, La Jolla CA, USA). Mean 
percentage staining and difference in staining between 
tissues was calculated with One-way ANOVA with 
post-hoc Bonferroni correction. In all tests, results were 
considered statistically significant at the level of P<0.05.
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